Atezolizumab Injection [Tecentriq]

DRUG4 trials

Sponsors

Chonnam National University Hospital, Spanish Oncology Genito-Urinary Group, Fudan University, Nykode Therapeutics ASA

Conditions

Bladder CancerCervical CancerHPV-Related Cervical CarcinomaHPV-Related MalignancyHepatocellular CarcinomaLung Neoplasm Malignant

Phase 2

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Active, not recruitingNCT04186013

Spanish Oncology Genito-Urinary GroupBladder Cancer

Start: 2019-09-18End: 2027-05-31Target: 39Updated: 2022-10-26

Efficacy and Safety of T+A+RAD in HCC

Fudan UniversityHepatocellular Carcinoma

Start: 2022-01-12End: 2023-12-31Target: 42Updated: 2022-05-31

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

WithdrawnNCT06099418

Nykode Therapeutics ASACervical Cancer, HPV-Related Cervical Carcinoma, HPV-Related Malignancy

Start: 2024-04-18End: 2028-05-31Updated: 2024-09-20

Phase 4

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

CompletedNCT04059887

Chonnam National University HospitalLung Neoplasm Malignant

Start: 2019-12-18End: 2022-06-30Updated: 2023-02-08

Related Papers

Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study.

Journal of Clinical Oncology2024-06-01

Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4).

Journal of Clinical Oncology2024-06-01

Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4).

Journal of Clinical Oncology2022-06-017 citations